Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712490 · ClinicalTrials.gov registry record · Phase 3
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,334
- Enrollment target
NCT01712490 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 1,334 participants.
The verdict
NCT01712490, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,334 participants
- Enrollment target
Study Summary
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin \[Adriamycin\],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Interventions
- DRUG doxorubicin
- DRUG brentuximab vedotin
- DRUG vinblastine
- DRUG dacarbazine
- DRUG bleomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,334 participants |
| Start Date | 2012-11-09 |
| Est. Completion | 2026-02-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712490
The ClinicalTrials.gov registry entry for NCT01712490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which doxorubicin is the first listed.
NCT01712490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712490 about?
NCT01712490 is a clinical study titled "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma". This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (ADCETRIS®) plus AVD (doxorubicin \[Adriamycin\], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtaine...
What is the current status of trial NCT01712490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,334 participants. The study started on 2012-11-09. Estimated completion is 2026-02-02.
What interventions are being tested in trial NCT01712490?
The interventions under investigation include: doxorubicin (DRUG), brentuximab vedotin (DRUG), vinblastine (DRUG), dacarbazine (DRUG), bleomycin (DRUG).
Who is sponsoring clinical trial NCT01712490?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.